Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cenexi will manufacture and process the peptides, produce the sterile emulsion and package the clinical batches of CoVepiT being used in the ongoing Phase 1 clinical trial and potentially for further clinical phases, subject to positive results of the Phase 1.
Lead Product(s): CoVepiT
Therapeutic Area: Infections and Infectious Diseases Product Name: OSE13E
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: OSE Immunotherapeutics SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 30, 2021